The gene therapy company CombiGene announced yesterday that it has submitted a PCT application to protect the vectors developed within the lipodystrophy project CGT2. This application opens up for future patent protection in approximately 150 countries. CombiGene’s CEO Jan Nilsson informs BioStock about the progress of the project and the long-term importance of potentially securing almost global patent protection.
